For laboratory research use only. Not for human consumption.

What Is PT-141?

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide that activates melanocortin receptors in the central nervous system. Its research history is one of the more unusual stories in peptide science — the compound was discovered accidentally during tanning peptide studies and went on to become the subject of multiple Phase 3 clinical trials.

Melanocortin Receptor Research

PT-141 works through the melanocortin receptor system — a family of receptors found throughout the central nervous system and peripheral tissues. Specifically, research has focused on its activation of MC3R and MC4R receptors, which are expressed in the hypothalamus and other brain regions. What makes this mechanism noteworthy in the research literature is that it operates through central neural pathways rather than peripheral vascular mechanisms. Published studies by Molinoff et al. (2003) established this central mechanism of action, distinguishing melanocortin agonists as a distinct class of research compounds.

Research Areas

Key areas of investigation documented in the published literature.

Neural Signaling Pathways

The melanocortin system is one of the brain's most fundamental signaling networks. MC3R and MC4R receptors are involved in a range of neural processes including energy homeostasis, feeding behavior, and autonomic nervous system regulation. By studying how PT-141 activates these specific receptors, researchers gain insight into how melanocortin signaling operates at the molecular level. Phase 1 research by Diamond et al. (2004) and later Phase 3 RECONNECT trials generated clinical-grade data on melanocortin receptor activation in human subjects, making PT-141 one of the most thoroughly characterized melanocortin agonists in the published literature.

How PT-141 Was Discovered

PT-141's origin story starts with Melanotan II, a peptide being studied at the University of Arizona for its effects on melanocortin-mediated pigmentation. During those clinical studies in the late 1990s, researchers observed unexpected physiological responses that appeared to be mediated through central melanocortin receptors rather than the pigmentation pathway they were investigating. This serendipitous finding led scientists to develop PT-141 as a focused analog — retaining the melanocortin receptor activity while reducing pigmentation effects. The compound went on to be studied in multiple clinical trials, generating one of the most comprehensive datasets on melanocortin agonism in the research literature.

Explore the Research

Dive deeper into the published literature and compound profiles.

For laboratory research use only. This content is provided for educational purposes about ongoing scientific research. Not for human consumption.